165 related articles for article (PubMed ID: 29093011)
1. Primary Immunoprevention of Epithelial Ovarian Carcinoma by Vaccination against the Extracellular Domain of Anti-Müllerian Hormone Receptor II.
Mazumder S; Johnson JM; Swank V; Dvorina N; Martelli E; Ko J; Tuohy VK
Cancer Prev Res (Phila); 2017 Nov; 10(11):612-624. PubMed ID: 29093011
[TBL] [Abstract][Full Text] [Related]
2. Regulation of Murine Ovarian Epithelial Carcinoma by Vaccination against the Cytoplasmic Domain of Anti-Müllerian Hormone Receptor II.
Sakalar C; Mazumder S; Johnson JM; Altuntas CZ; Jaini R; Aguilar R; Naga Prasad SV; Connolly DC; Tuohy VK
J Immunol Res; 2015; 2015():630287. PubMed ID: 26618181
[TBL] [Abstract][Full Text] [Related]
3. The human Müllerian inhibiting substance type II receptor as immunotherapy target for ovarian cancer. Validation using the mAb 12G4.
Kersual N; Garambois V; Chardès T; Pouget JP; Salhi I; Bascoul-Mollevi C; Bibeau F; Busson M; Vié H; Clémenceau B; Behrens CK; Estupina P; Pèlegrin A; Navarro-Teulon I
MAbs; 2014; 6(5):1314-26. PubMed ID: 25517316
[TBL] [Abstract][Full Text] [Related]
4. LSR Antibody Therapy Inhibits Ovarian Epithelial Tumor Growth by Inhibiting Lipid Uptake.
Hiramatsu K; Serada S; Enomoto T; Takahashi Y; Nakagawa S; Nojima S; Morimoto A; Matsuzaki S; Yokoyama T; Takahashi T; Fujimoto M; Takemori H; Ueda Y; Yoshino K; Morii E; Kimura T; Naka T
Cancer Res; 2018 Jan; 78(2):516-527. PubMed ID: 29187404
[TBL] [Abstract][Full Text] [Related]
5. Patterns of Müllerian Inhibiting Substance Type II and Candidate Type I Receptors in Epithelial Ovarian Cancer.
Basal E; Ayeni T; Zhang Q; Langstraat C; Donahoe PK; Pepin D; Yin X; Leof E; Cliby W
Curr Mol Med; 2016; 16(3):222-31. PubMed ID: 26917267
[TBL] [Abstract][Full Text] [Related]
6. Targeting myeloid cells in the tumor microenvironment enhances vaccine efficacy in murine epithelial ovarian cancer.
Khan AN; Kolomeyevskaya N; Singel KL; Grimm MJ; Moysich KB; Daudi S; Grzankowski KS; Lele S; Ylagan L; Webster GA; Abrams SI; Odunsi K; Segal BH
Oncotarget; 2015 May; 6(13):11310-26. PubMed ID: 25888637
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy of ovarian cancer with a monoclonal antibody specific for the extracellular domain of anti-Müllerian hormone receptor II.
Mazumder S; Swank V; Komar AA; Johnson JM; Tuohy VK
Oncotarget; 2020 May; 11(20):1894-1910. PubMed ID: 32499873
[TBL] [Abstract][Full Text] [Related]
8. Pyridoxine 5'-phosphate oxidase is a novel therapeutic target and regulated by the TGF-β signalling pathway in epithelial ovarian cancer.
Zhang L; Zhou D; Guan W; Ren W; Sun W; Shi J; Lin Q; Zhang J; Qiao T; Ye Y; Wu Y; Zhang Y; Zuo X; Connor KL; Xu G
Cell Death Dis; 2017 Dec; 8(12):3214. PubMed ID: 29238081
[TBL] [Abstract][Full Text] [Related]
9. Effect of targeted ovarian cancer immunotherapy using ovarian cancer stem cell vaccine.
Wu D; Wang J; Cai Y; Ren M; Zhang Y; Shi F; Zhao F; He X; Pan M; Yan C; Dou J
J Ovarian Res; 2015 Oct; 8():68. PubMed ID: 26497895
[TBL] [Abstract][Full Text] [Related]
10. NSAID-activated gene 1 mediates pro-inflammatory signaling activation and paclitaxel chemoresistance in type I human epithelial ovarian cancer stem-like cells.
Kim KH; Park SH; Do KH; Kim J; Choi KU; Moon Y
Oncotarget; 2016 Nov; 7(44):72148-72166. PubMed ID: 27708225
[TBL] [Abstract][Full Text] [Related]
11. Formulation of an ovarian cancer vaccine with the squalene-based AddaVax adjuvant inhibits the growth of murine epithelial ovarian carcinomas.
Mazumder S; Swank V; Dvorina N; Johnson JM; Tuohy VK
Clin Exp Vaccine Res; 2022 May; 11(2):163-172. PubMed ID: 35799868
[TBL] [Abstract][Full Text] [Related]
12. Notch and TGFβ form a positive regulatory loop and regulate EMT in epithelial ovarian cancer cells.
Zhou J; Jain S; Azad AK; Xu X; Yu HC; Xu Z; Godbout R; Fu Y
Cell Signal; 2016 Aug; 28(8):838-49. PubMed ID: 27075926
[TBL] [Abstract][Full Text] [Related]
13. Ovarian Cancer Stem Cells with High ROR1 Expression Serve as a New Prophylactic Vaccine for Ovarian Cancer.
Wu D; Yu X; Wang J; Hui X; Zhang Y; Cai Y; Ren M; Guo M; Zhao F; Dou J
J Immunol Res; 2019; 2019():9394615. PubMed ID: 31008116
[TBL] [Abstract][Full Text] [Related]
14. Targeting HSF1 leads to an antitumor effect in human epithelial ovarian cancer.
Chen YF; Wang SY; Yang YH; Zheng J; Liu T; Wang L
Int J Mol Med; 2017 Jun; 39(6):1564-1570. PubMed ID: 28487934
[TBL] [Abstract][Full Text] [Related]
15. DNA hypomethylation-mediated activation of Cancer/Testis Antigen 45 (CT45) genes is associated with disease progression and reduced survival in epithelial ovarian cancer.
Zhang W; Barger CJ; Link PA; Mhawech-Fauceglia P; Miller A; Akers SN; Odunsi K; Karpf AR
Epigenetics; 2015; 10(8):736-48. PubMed ID: 26098711
[TBL] [Abstract][Full Text] [Related]
16. [Screening and sero-immunoscreening of ovarian epithelial cancer associative antigens].
Yang ZJ; Yang G; Jiang YM; Ran YL; Yang ZH; Zhang W; Zhang JQ; Pan ZM; Li L
Zhonghua Fu Chan Ke Za Zhi; 2007 Dec; 42(12):834-9. PubMed ID: 18476518
[TBL] [Abstract][Full Text] [Related]
17. Human amniotic epithelial cells inhibit growth of epithelial ovarian cancer cells via TGF‑β1-mediated cell cycle arrest.
Bu S; Zhang Q; Wang Q; Lai D
Int J Oncol; 2017 Nov; 51(5):1405-1414. PubMed ID: 29048644
[TBL] [Abstract][Full Text] [Related]
18. Targeting "Retired Antigens" for Cancer Immunoprevention.
Shoemaker RH; Forsthuber TG
Cancer Prev Res (Phila); 2017 Nov; 10(11):607-608. PubMed ID: 29093010
[TBL] [Abstract][Full Text] [Related]
19. CAR T Cells Targeting MISIIR for the Treatment of Ovarian Cancer and Other Gynecologic Malignancies.
Rodriguez-Garcia A; Sharma P; Poussin M; Boesteanu AC; Minutolo NG; Gitto SB; Omran DK; Robinson MK; Adams GP; Simpkins F; Powell DJ
Mol Ther; 2020 Feb; 28(2):548-560. PubMed ID: 31870622
[TBL] [Abstract][Full Text] [Related]
20. Misregulation of polo-like protein kinase 1, P53 and P21WAF1 in epithelial ovarian cancer suggests poor prognosis.
Zhang R; Shi H; Ren F; Liu H; Zhang M; Deng Y; Li X
Oncol Rep; 2015 Mar; 33(3):1235-42. PubMed ID: 25592872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]